Literature DB >> 2254382

Adriamycin uptake and metabolism in organotypic culture of A549 human adenocarcinoma cells according to the exposure time.

S Chevillard1, P Vielh, G Bastian, J Coppey.   

Abstract

In organotypic cultures (nodules) of A 549 human lung adenocarcinoma cells, the long-term cytotoxicity of Adriamycin is strongly improved by shortening the exposure time to the drug. In order to gain insight into the mechanisms of Adriamycin toxicity in this system, we have examined the drug uptake, retention and metabolism by fluorescence microscopy and HPLC analysis. A 549 nodules efficiently metabolize Adriamycin, two major metabolites, adriamycinol and an aglycone derivative, as yet chemically unidentified, are formed and efficiently excreted. Kinetic data show that a long exposure to Adriamycin triggers its efflux from both the nucleus and the cytoplasm while stimulating its metabolism. Therefore, a long exposure time to the drug appears to trigger a process of cellular detoxification by favouring its excretion from the cells via increased metabolism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2254382     DOI: 10.1007/bf01637086

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  38 in total

Review 1.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Microsomal reductive glycosidase.

Authors:  N R Bachur; M Gee
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

3.  Pharmacokinetics and metabolism of adriamycin in man.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

4.  Long term regeneration of cis-platinum and X ray treated human tumor nodules maintained in continuous organotypic culture.

Authors:  R Beaupain; C Baroche; D Lagarde
Journal:  Int J Radiat Oncol Biol Phys       Date:  1983-05       Impact factor: 7.038

Review 5.  The anthracycline antineoplastic drugs.

Authors:  R C Young; R F Ozols; C E Myers
Journal:  N Engl J Med       Date:  1981-07-16       Impact factor: 91.245

6.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

Authors:  R F Greene; J M Collins; J F Jenkins; J L Speyer; C E Myers
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

7.  Doxorubicin resistance in P388 leukemia--evidence for reduced drug influx.

Authors:  A Ramu; H B Pollard; L M Rosario
Journal:  Int J Cancer       Date:  1989-09-15       Impact factor: 7.396

8.  Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells.

Authors:  R Baurain; A Zenebergh; A Trouet
Journal:  J Chromatogr       Date:  1978-09-21

9.  Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline.

Authors:  M Broggini; M Grandi; P Ubezio; C Geroni; F C Giuliani; M D'Incalci
Journal:  Biochem Pharmacol       Date:  1988-12-01       Impact factor: 5.858

10.  Effects of combined treatments of cis-diamminedichloroplatinum(II), 5-fluorouracil, and X-rays on growth of human cancer nodules maintained in continuous organotypic culture.

Authors:  R Beaupain; C Dionet
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

View more
  5 in total

1.  Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.

Authors:  M J Kuffel; J M Reid; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Soluble ECM promotes organotypic formation in lung alveolar model.

Authors:  Jonard C Valdoz; Nicholas A Franks; Collin G Cribbs; Dallin J Jacobs; Ethan L Dodson; Connor J Knight; P Daniel Poulson; Seth R Garfield; Benjamin C Johnson; Brandon M Hemeyer; Miranda T Sudo; Jordan A Saunooke; Braden C Kartchner; Aubrianna Saxton; Mary L Vallecillo-Zuniga; Matheus Santos; Brandon Chamberlain; Kenneth A Christensen; Greg P Nordin; A Sampath Narayanan; Ganesh Raghu; Pam M Van Ry
Journal:  Biomaterials       Date:  2022-03-16       Impact factor: 15.304

3.  Intracellular localization, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells.

Authors:  A Seidel; M Hasmann; R Löser; A Bunge; B Schaefer; I Herzig; K Steidtmann; M Dietel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

4.  Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.

Authors:  T Yamaoka; M Hanada; S Ichii; S Morisada; T Noguchi; Y Yanagi
Journal:  Jpn J Cancer Res       Date:  1999-06

5.  Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.

Authors:  T Yamaoka; M Hanada; S Ichii; S Morisada; T Noguchi; Y Yanagi
Journal:  Jpn J Cancer Res       Date:  1998-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.